Aethlon Medical (NASDAQ:AEMD) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

Aethlon Medical, Inc. (NASDAQ:AEMD)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $8.19 and traded as low as $2.42. Aethlon Medical shares last traded at $2.46, with a volume of 87,377 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Aethlon Medical has a consensus rating of “Reduce” and a consensus price target of $560.00.

Aethlon Medical Stock Down 9.9%

The company has a market capitalization of $2.39 million, a P/E ratio of -0.11 and a beta of 1.60. The business has a 50 day moving average of $3.63 and a 200 day moving average of $8.19.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings data on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.70) by ($2.04). On average, research analysts anticipate that Aethlon Medical, Inc. will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Aethlon Medical

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to its most recent 13F filing with the SEC. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is currently owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.